Universal antigen-presenting cells and uses thereof
Universal antigen presenting cells engineered to express CD48, CS1, mbIL-21, and 41BBL effectively expand NK cells for cancer therapy, addressing the challenge of producing clinically relevant NK cell numbers with enhanced tumor targeting and reduced autoimmunity.
Patent Information
- Application Number
- JP2020544206
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-02-21
- Filing Date
- 2019-02-21
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2039-02-21
AI Technical Summary
Existing methods struggle to efficiently produce and expand clinically relevant numbers of natural killer (NK) cells for cancer immunotherapy while maintaining tight control to prevent unintentional cytotoxicity and autoimmunity.
The development of universal antigen presenting cells (UAPCs) engineered to express CD48, CS1, membrane-bound interleukin-21 (mbIL-21), and 41BB ligand (41BBL) to stimulate and expand NK cells, along with the use of cytokines like IL-2 and specific cell ratios for optimal expansion.
The UAPCs achieve a 1000-fold expansion of NK cells over 14-21 days, enhancing their cytotoxicity and specificity against tumors without significant T cell proliferation, providing a robust platform for cancer immunotherapy.
Smart Images

Figure 0007591405000003 
Figure 0007591405000004 
Figure 0007591405000005
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional Patent Application No. 62 / 633,587, filed February 21, 2018, which is incorporated by reference in its entirety.
[0002] The sequence listing, which is in KB (measured in Microsoft Windows) and is contained in a file named "UTFCP1355WO_ST25.txt" created on February 21, 2019, is filed herewith by electronic submission and is incorporated herein by reference. [Background technology]
[0003] The present invention relates generally to the fields of medicine and immunology. More particularly, the present invention relates to antigen-presenting cells and uses thereof, such as the expansion of natural killer (NK) cells.
[0004] Natural killer (NK) cells, in contrast to T cells, are highly effective in tumor immunosurveillance because they do not require prior exposure to antigens to be activated. Although no prior activation is required, their tremendous killing power requires tight control to forestall unintended cytotoxicity and autoimmunity. Generating clinically sufficient and optimally functioning NK cells is another obstacle. Therefore, it is necessary to focus on the molecular mechanisms that govern the NK cell function to distinguish between "resistant" and "sensitive" target cells in order to design helper cells that improve NK cell-mediated cancer immunotherapy. Summary of the Invention
[0005] Thus, certain embodiments of the present disclosure provide methods and compositions for the production, expansion, quality control and functional characterization of clinical grade NK cells for cell therapy and immunotherapy purposes.
[0006] In a first embodiment, universal antigen presenting cells (UAPCs) are provided that are engineered to express (1) CD48 and / or CS1 (CD319), (2) membrane-bound interleukin-21 (mbIL-21), and (3) 41BB ligand (41BBL). In some embodiments, the UAPCs express CD48. In other embodiments, the UAPCs express CS1. In certain embodiments, the UAPCs express CD48 and CS1.
[0007] In some embodiments, the UAPCs do not essentially express endogenous HLA class I, II, or CD1d molecules. In certain embodiments, the UAPCs express ICAM-1 (CD54) and LFA-3 (CD58).
[0008] In certain embodiments, the UAPC is further defined as aAPC derived from a leukemia cell. In some embodiments, the UAPC derived from a leukemia cell is further defined as a K562 cell.
[0009] In some embodiments, the manipulation is further defined as retroviral transduction. In some embodiments, the retroviral transduction is further defined as the introduction of a viral construct of SEQ ID NO: 1 and / or SEQ ID NO: 2. In certain embodiments, the UAPCs are irradiated.
[0010] In a further embodiment, a method for expanding immune cells is provided, the method comprising culturing the immune cells in the presence of an effective amount of a UAPC of the above embodiments (e.g., a universal antigen presenting cell (UAPC) engineered to express (1) CD48 and / or CS1 (CD319), (2) membrane-bound interleukin-21 (mbIL-21), and (3) 41BB ligand (41BBL). In some embodiments, the immune cells and UAPC are cultured at a ratio of 3:1 to 1:3, e.g., 3:1, 3:2, 1:1, 1:2, or 1:3. In certain embodiments, the immune cells and UAPC are cultured at a ratio of 1:2.
[0011] In some embodiments, the expansion is in the presence of IL-2. In specific embodiments, IL-2 is present at a concentration of 10-500 U / mL (e.g., 10-25, 25-50, 50-75, 75-10, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, or 400-500 U / mL). In certain embodiments, IL-2 is present at a concentration of 100-300 U / mL. In certain embodiments, IL-2 is present at a concentration of 200 U / mL. In some embodiments, IL-2 is recombinant human IL-2. In specific embodiments, IL-2 is replenished every 2-3 days (e.g., every 2 or 3 days).
[0012] In certain embodiments, the UAPC is added at least twice. In some embodiments, the immune cells are NK cells or T cells. In certain embodiments, the immune cells are NK cells.
[0013] In certain embodiments, the immune cells are derived from cord blood (CB), peripheral blood (PB), stem cells or bone marrow. In specific embodiments, the stem cells are induced pluripotent stem cells. In some embodiments, the immune cells are obtained from CB. In certain embodiments, the CB is pooled from 2 or more individual cord blood units. In specific embodiments, the CB is pooled from 3, 4, 5, 6, 7 or 8 individual cord blood units.
[0014] In some embodiments, the NK cells are CB mononuclear cells (CBMCs). In certain embodiments, the NK cells further comprise CD56 + Defined as NK cells.
[0015] In certain embodiments, the method is carried out in serum-free medium.
[0016] In further embodiments, the immune cells are engineered to express a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises the antigen binding domain of CD19, CD123, mesothelin, CD5, CD47, CLL-1, CD33, CD99, U5snRNP200, CD200, CS1, BAFF-R, ROR-1 or BCMA. In some embodiments, the CAR is a humanized CAR. In some embodiments, the CAR comprises IL-15. In certain embodiments, the CAR comprises a suicide gene. In some embodiments, the suicide gene is CD20, CD52, EGFRv3 or inducible caspase 9.
[0017] Further provided herein are populations of immune cells generated and expanded according to the above embodiments (e.g., culturing the immune cells in the presence of an effective amount of a UAPC of the above embodiments (e.g., a universal antigen presenting cell (UAPC) engineered to express (1) CD48 and / or CS1 (CD319), (2) membrane-bound interleukin-21 (mbIL-21), and (3) 41BB ligand (41BBL)).
[0018] In another embodiment, a pharmaceutical composition is provided comprising a population of expanded immune cells of the above embodiments and a pharma- ceutically acceptable carrier.Further provided herein is a composition comprising an effective amount of the expanded immune cells of the above embodiments for use in treating a disease or disorder in a subject.
[0019] Further embodiments provide methods of treating a disease or disorder in a subject, comprising administering to the subject a therapeutically effective amount of the expanded immune cells of the above embodiments.
[0020] In some embodiments, the disease or disorder is cancer, inflammation, graft-versus-host disease, graft rejection, autoimmune disorder, immunodeficiency, B-cell malignancy or infectious disease. In certain embodiments, the cancer is leukemia. In some embodiments, the leukemia is acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) or chronic myeloid leukemia (CML). In certain embodiments, the disorder is graft-versus-host disease (GVHD). In some embodiments, the disorder is multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, type I diabetes, systemic lupus erythematosus, contact hypersensitivity, asthma or Sjogren's syndrome. In some embodiments, the subject is a human.
[0021] In certain embodiments, the immune cells are allogeneic. In some embodiments, the immune cells are autologous. In some embodiments, the immune cells are NK cells or T cells.
[0022] In further embodiments, the method further comprises administering at least one second therapeutic agent.In some embodiments, the at least one second therapeutic agent is a therapeutically effective amount of anti-cancer agent, immunomodulatory agent or immunosuppressant agent.In certain embodiments, the anti-cancer agent is chemotherapy, radiation therapy, gene therapy, surgery, hormone therapy, anti-angiogenesis therapy or immunotherapy.
[0023] In some embodiments, the immunosuppressant is a calcineurin inhibitor, an mTOR inhibitor, an antibody, a chemotherapeutic agent, radiation, a chemokine, an interleukin, or an inhibitor of a chemokine or interleukin.
[0024] In further embodiments, immune cells and / or at least one second therapeutic agent are administered intravenously, intraperitoneally, intratracheally, intratumorally, intramuscularly, endoscopically, intralesional, percutaneously, subcutaneously, regionally, or by direct injection or perfusion.In some embodiments, the second therapeutic agent is an antibody.In certain embodiments, the antibody is a monoclonal antibody, a bispecific antibody, or a trispecific antibody.In some embodiments, the antibody is rituximab.
[0025] Other objects, features and advantages of the present invention will become apparent from the following detailed description, however, it should be noted that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration only, since various changes and modifications that do not exceed the spirit and scope of the present invention will become apparent to those skilled in the art from this detailed description.
[0026] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The present disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. [Brief description of the drawings]
[0027] [Figure 1A]Zipper model of the interaction between human natural killer cell receptors and target cell ligands. Human NK cells interact with target cells through a number of receptors, including killer immunoglobulin receptors (KIRs), natural cytotoxicity receptors (NCRs), NKG2 family receptors, nectin-binding receptors, and SLAM family receptors. Receptors on NK cells are either activating (KIR2DL4, KIR3DS1, NKp30, NKp44, NKp46, NKp80, CD94-NKG2C, DAP10, NKG2D, DAP10, CRTAM, DNAM, 2B4, NTB-A, CD3 zeta, CD100, CD160) or inhibitory (KIR2DL1 / 2 / 3 / 5A / 5B, KIR3DL1 / 2 / 3, CD94-NKG2A, TIGIT, CD96, CEACAM-1, ILT2 / LILRB1, KLRG1, LAIR1, CD161, Siglec-3 / 7 / 9). [Figure 1B] Zipper model of the interaction between human natural killer cell receptors and target cell ligands. Human NK cells interact with target cells through a number of receptors, including killer immunoglobulin receptors (KIRs), natural cytotoxicity receptors (NCRs), NKG2 family receptors, nectin-binding receptors, and SLAM family receptors. Receptors on NK cells are either activating (KIR2DL4, KIR3DS1, NKp30, NKp44, NKp46, NKp80, CD94-NKG2C, DAP10, NKG2D, DAP10, CRTAM, DNAM, 2B4, NTB-A, CD3 zeta, CD100, CD160) or inhibitory (KIR2DL1 / 2 / 3 / 5A / 5B, KIR3DL1 / 2 / 3, CD94-NKG2A, TIGIT, CD96, CEACAM-1, ILT2 / LILRB1, KLRG1, LAIR1, CD161, Siglec-3 / 7 / 9). [Figure 1C]Zipper model of the interaction between human natural killer cell receptors and target cell ligands. Human NK cells interact with target cells through a number of receptors, including killer immunoglobulin receptors (KIRs), natural cytotoxicity receptors (NCRs), NKG2 family receptors, nectin-binding receptors, and SLAM family receptors. Receptors on NK cells are either activating (KIR2DL4, KIR3DS1, NKp30, NKp44, NKp46, NKp80, CD94-NKG2C, DAP10, NKG2D, DAP10, CRTAM, DNAM, 2B4, NTB-A, CD3 zeta, CD100, CD160) or inhibitory (KIR2DL1 / 2 / 3 / 5A / 5B, KIR3DL1 / 2 / 3, CD94-NKG2A, TIGIT, CD96, CEACAM-1, ILT2 / LILRB1, KLRG1, LAIR1, CD161, Siglec-3 / 7 / 9).
[0028] [Figure 2A] Fold expansion of fresh or frozen NK cells with IL-2 or APC. [Figure 2B] Fold expansion of fresh or frozen NK cells with IL-2 or APC. [Figure 2C] Flow cytometry on days 0, 7 or 14 for CD3 and CD56 expression on NK cells. [Figure 2D] Cell counts of NT-NK cells or SG4-NK cells stimulated with APC. [Figure 2E] Proliferation kinetics of NK cells stimulated with clone 9 APC or UAPC.
[0029] [Figure 3A] Flow cytometry of parental K562 cells for the indicated markers. No expression of mb-IL21, 41BBL, CD48 and SLAMF7 (CS1) was observed. [Figure 3B] Flow cytometry analysis of APCs after clone 46 transduction (mbIL-21, 41BBL). [Figure 3C] Flow cytometric analysis of APCs following transduction of uAPC constructs to express CD48 (nmIL-21, 41BBL and CD48). [Figure 3D] Flow cytometric analysis of APCs following transduction of uAPC2 constructs to express CS1 (mbIL-21, 41BBL and CS1).
[0030] [Figure 4A] Map and annotation of the MMLV-retroviral transfer construct. Retroviral transfer vector for mb-IL21. [Figure 4B] Map and annotation of the MMLV-retroviral transfer construct. Retroviral transfer vector for 41BBL. [Figure 4C] Map and annotation of the MMLV-retroviral transfer construct. Retroviral transfer vector for CD48-Katushka. [Figure 4D] Map and annotation of the MMLV-retroviral transfer construct. Retroviral transfer vector for CS1-EGFP. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] In this study, NK cells were initially characterized for their antitumor and antiallolytic functions that are distinct from other components of the innate immune compartment. The myriad immune receptors that govern NK cell behavior are illustrated as a "shipper" graph in Figure 1. Their suite of signaling agents can be broadly categorized into two major groups: activating and inhibitory. Depending on the structure and mode of signaling, these categories are further divided into related families of immune receptors. Although the membrane proteome of NK cells is yet to be fully characterized, functional redundancy within the NK cell "zipper" was exploited to regulate cytolytic functions in a complex and dynamic equilibrium between complementary and antagonistic pathways.
[0032] Thus, certain embodiments of the present disclosure provide methods and compositions for the production, expansion, quality control and functional characterization of clinical grade NK cells for cell therapy and immunotherapy. Expanding and forming clinically relevant numbers of NK cells for infusion into patients while meeting time constraints is difficult in the best of circumstances. In certain aspects, the methods and compositions of the present disclosure detail the technical process of NK cell production, the details and kinetics of NK cell expansion that can be achieved, and molecular characterization to verify the success of cell formation.
[0033] In a further embodiment, a robust platform technology is provided herein that is embodied as a universal antigen-presenting cell (UAPC) for conditioning, shaping, and weaponizing human natural killer (NK) cells against tumors. "UAPC" herein refers to an antigen-presenting cell designed for optimized expansion of immune cells such as NK cells. The UAPC was created with a unique combination of costimulatory molecules to overcome inhibitory signals and induce optimal and specific killing function of NK cells. Extensive studies have shown that the UAPC fine-tunes the NK cell mechanism and improved tumor elimination. The UAPC can be used for NK cell-mediated cancer immunotherapy.
[0034] An exemplary APC is generated by forced expression of membrane-bound interleukin 21 (mbIL-21) and 4-1BB ligand in NK cell-sensitive K562 antigen-presenting cell line (APC) (referred to as clone 46). In another embodiment, UAPC was generated by forced expression of mbIL-21, 4-1BB ligand and CD48 in K562 cells (referred to as universal APC (UAPC)). In another embodiment, UAPC was generated by forced expression of mbIL-21, 4-1BB ligand and CS1 in K562 cells (referred to as UAPC2). These UAPC can be generated to express mbIL-21, 41BBL and NK cell-specific antigens (e.g., SLAM family antigens (Table 1)).
[0035] The UAPC platform can also be applied to expand other immune effectors, including T cells (e.g., alpha-beta and gamma-delta T cells). These immune cells (e.g., NK cells and T cells) can be derived from peripheral blood, umbilical cord blood, bone marrow, or stem cells (including induced pluripotent stem cells). These immune cells can be subjected to ex vivo expansion and activation using the UAPC, which is necessary for culture to reach meaningful numbers for clinically relevant applications such as cancer immunotherapy.
[0036] Thus, the present disclosure provides a series of helper cell lines designed and manufactured to condition, regulate, prime and expand human immune cells (e.g., NK cells) for cancer immunotherapy. I. Definition
[0037] As used herein, "essentially free" with respect to a particular component is used herein to mean that the particular component is not intentionally formulated in a composition and / or is present only as an impurity or in trace amounts.Thus, the total amount of the particular component resulting from any unintentional inclusion in a composition is well below 0.05%, preferably below 0.01%.Most preferred is a composition in which the amount of the particular component is not detectable by standard analytical methods.
[0038] As used herein, "a" or "an" can mean one or more. When used in the claims, the words "a" or "an" when used in conjunction with the word "comprising" can mean one or more than one.
[0039] The use of the term "or" in the claims is used to mean "and / or" unless expressly indicated to refer to alternatives only or the alternatives are not mutually exclusive, however, the present disclosure supports the definition and "and / or" to refer to alternatives only. As used herein, "another" can mean at least one second or more. The terms "about," "substantially," and "approximately" generally mean the stated value plus or minus 5%.
[0040] "Immune disorder," "immune-related disorder," or "immune-mediated disorder" refers to a disorder in which the immune response plays a significant role in the development or progression of the disease. Immune-mediated disorders include autoimmune disorders, allograft rejection, graft-versus-host disease, and inflammatory and allergic conditions.
[0041] An "immune response" is the response of a cell of the immune system (e.g., a B cell or T cell or an innate immune cell) to a stimulus. In one embodiment, the response is specific for a particular antigen (an "antigen-specific response").
[0042] "Autoimmune disease" refers to a disease in which the immune system mounts an immune response (e.g., a B cell response or a T cell response) against antigens that are part of the normal host (i.e., self-antigens), resulting in damage to tissues. Self-antigens can be derived from host cells or from commensal organisms, such as microorganisms that normally colonize mucosal surfaces (known as commensals).
[0043] "Treating" a disease or condition or treatment thereof refers to the implementation of a protocol that may include administering one or more drugs to a patient with the aim of alleviating the signs or symptoms of the disease. Desirable effects of treatment include slowing the progression of the disease, reducing or alleviating the disease state, and remission or improving prognosis. Alleviation can occur before the signs or symptoms of the disease or condition appear, as well as after they appear. Thus, "treating" or "treatment" can include "preventing" or the "prevention" of a disease or undesirable condition. Furthermore, "treating" or "treatment" does not require complete alleviation of signs or symptoms, does not require a cure, and specifically includes protocols that have only a marginal effect on the patient.
[0044] The term "therapeutic effect" or "therapeutically effective" as used throughout this application refers to promoting or improving the health of a subject with respect to the medical treatment of the condition. This includes, but is not limited to, reducing the frequency or severity of signs or symptoms of a disease. For example, treating cancer can include, for example, reducing tumor size, reducing the invasiveness of a tumor, reducing the rate of growth of a cancer, or preventing metastasis. Treating cancer can also refer to extending the survival time of a subject with cancer.
[0045] "Subject" and "patient" refer to humans or non-humans (e.g., primates, mammals, and vertebrates). In certain embodiments, the subject is a human.
[0046] The phrase "pharmaceutical or pharmacologically acceptable" refers to molecular entities and compositions that do not cause side effects, allergic reactions or other adverse reactions when administered to animals, including humans as appropriate.The preparation of pharmaceutical compositions containing antibodies or additional active ingredients is known to those skilled in the art in light of the present disclosure.Furthermore, it is understood that for administration to animals (e.g., humans), preparations should meet the standards of sterility, pyrogenicity, general safety and purity as required by the FDA Office of Biological Standards.
[0047] As used herein, "pharmaceutical acceptable carrier" includes any and all aqueous solvents (e.g., water, alcoholic / aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, etc.), non-aqueous solvents (e.g., propylene glycol, polyethylene glycol, vegetable oils and injectable organic esters such as ethyl oleate), dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial or antifungal agents, antioxidants, chelating agents and inert gases), isotonicity agents, absorption retarding agents, salts, drugs, drug stabilizers, gels, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, fluid and nutritional supplements, such materials and combinations thereof, as may be known to those skilled in the art. The pH and exact concentration of various components in the pharmaceutical composition are adjusted according to well-known parameters.
[0048] The term "haplotyping or tissue typing" refers to methods used to identify a subject's haplotype or tissue type, for example, by determining which HLA locus (or loci) are expressed on the lymphocytes of a particular subject. HLA genes are located in the major histocompatibility complex (MHC), a region on the short arm of chromosome 6, and are involved in cell-cell interactions, immune responses, organ transplantation, cancer development, and susceptibility to disease. There are six loci important in transplantation, designated HLA-A, HLA-B, HLA-C and HLA-DR, HLA-DP, and HLA-DQ. At each locus, any of several different alleles may be present.
[0049] A widely used method for haplotyping uses polymerase chain reaction (PCR) to compare the subject's DNA with known segments of genes that code for MHC antigens. Variations in these regions of the genes determine the subject's tissue type or haplotype. Serological methods are also used to detect serologically defined antigens on cell surfaces. HLA-A, -B and -C determinants can be measured by known serological techniques. Briefly, lymphocytes from the subject (isolated from fresh peripheral blood) are incubated with antisera that recognize all known HLA antigens. The cells are spread on a tray with microscopic wells containing different types of antisera. The cells are incubated for 30 minutes, and then the incubation is complemented for an additional 60 minutes. If the lymphocytes have antigens on their surface that are recognized by the antibodies in the antisera, they are lysed. Dyes can be added to show changes in the permeability of the cell membrane and cell death. The pattern of cells destroyed by lysis indicates the degree of histological incompatibility. For example, if lymphocytes from a person being tested for HLA-A3 are disrupted in wells containing antisera to HLA-A3, the test is positive for this antigen group.
[0050] The term "antigen-presenting cell (APC)" refers to a class of cells that can present one or more antigens in the form of peptide-MHC complexes that can be recognized by specific effector cells of the immune system, thereby inducing an effective cellular immune response to the presented antigens. The term "APC" includes intact whole cells (e.g., macrophages, B cells, endothelial cells, activated T cells and dendritic cells), or naturally occurring or synthetic molecules that can present antigens (e.g., purified MHC class I molecules complexed with y2-microglobulin). II. Universal antigen-presenting cells
[0051] Some embodiments of the present disclosure relate to the generation and use of universal antigen presenting cells (UAPCs). UAPCs can be used for the expansion of immune cells (e.g., NK cells and T cells). UAPCs can be engineered to express membrane-bound IL-21 (mbIL-21) and 41BBL (CD137 ligand).
[0052] The UAPC may be engineered to express CD137 ligand and / or membrane-bound cytokine. The membrane-bound cytokine may be mIL-21 or mIL-15. In certain embodiments, the UAPC is engineered to express CD137 ligand and mIL-21. The APC may be derived from a cancer cell, such as a leukemia cell. The APC may not express endogenous HLA class I, II or CD1d molecules. The APC may express ICAM-1 (CD54) and LFA-3 (CD58). In particular, the APC may be a K562 cell (e.g., a K562 cell engineered to express CD137 ligand and mIL-21). The APC may be irradiated. The above engineering may be by any method known in the art, for example, by retroviral transduction.
[0053] Cytokines exert extremely potent regulation on all classes of immune cells, including NK cells, influencing cell fate, activity and the efficacy of cellular responses. The power of cytokine stimulation to activate NK cells confirms that their "native" effector functions are highly sensitive to environmental interventions and that priming can control NK cell behavior in vivo.
[0054] To address the issue of obtaining clinically relevant amounts of NK cells, the present method may use interleukin (IL-21) as a driver for NK cell expansion in the present UAPC platform technology. In humans, NK cell stimulation with IL-10 and IL-21 induces NKG2D expression in a STAT3-dependent manner. Although cytokine receptors share similar cell signaling components in many immune cells, NK cell-specific signaling depends on the IL-21 receptor-STAT3 relationship for proliferation.
[0055] Cytokine signaling is important for maintaining lymphocyte survival and proliferation. In vivo, IL-2 administration is the only FDA-approved method for expanding NK cells. Another potent NK cell activator, IL-15, is undergoing Phase I clinical trials as a potential IL-2 alternative, but may have significant toxicity after systemic administration. Besides significant toxicity, these cytokines also induce T cell proliferation while limiting NK cell survival. Despite sharing the same receptor for signaling, IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 receptors have different and specific effects on various cells. A. Membrane-bound IL-21
[0056] In certain embodiments, IL-21 may be used to generate the UAPCs when specifically activating NK cells. The IL-21 receptor (IL21R) is closely associated with the IL-2 receptor beta chain, which can signal by dimerizing with the common cytokine receptor gamma chain (gamma(c)), and is upregulated in activated human NK cells (cells primed for induction). Although IL-21, a type I cytokine, can regulate the function of T cells, B cells, and NK cells, the present study found that only human NK cells underwent significant expansion (i.e., 1000-fold over 21 days) via activation of the IL21 receptor signaling pathway. Conversely, IL21 stimulates the proliferation and proliferation of CD8 +Plays an important role in T cell reduction.
[0057] IL21R signaling is primarily driven by STAT3, a highly potent activator of cell proliferation. The IL21R-STAT3 relationship is driven by IL-21-induced STAT3 DNA binding to GAS and cis-inducible elements, verified by immunoprecipitation and western blotting with anti-phosphotyrosine antibodies. The molecular basis of IL21-mediated proliferation can be specifically traced to tyrosine 510 (Y510) on IL21R, which mediates IL-21-induced phosphorylation of STAT1 and STAT33. This mechanism is clearly demonstrated by the attenuated IL-21 response in Stat1 / Stat3 double knockout mice.
[0058] IL21R signaling is important for NK cytotoxicity. Human IL21R deficiency is associated with impaired cytolysis of 51Cr-labeled K562 target cells, whereas antibody-dependent cellular cytotoxicity is unaffected. Monogenic non-embryonic lethal deficiencies (loss-of-function mutations in IL21R) offer an excellent opportunity to define the innate NK cytolytic response and are therefore useful for modeling, enhancing and shaping the innate NK cytolytic response.
[0059] CD56 dim Cell populations and CD56 bright IL-21 signaling selectively shapes subsets of NK cells, even though both cell populations have similar numbers of surface IL21R. IL-21 induction of STAT1 and STAT3 phosphorylation is higher in CD56bright NK cells versus CD56dim NK cells. In contrast, IL-21 does not affect STAT5 activation, an IL-2-activated pathway that also drives T cell expansion. In addition to STAT3 activation, IL-21 signaling involves MAPK and PI3K pathways to induce expression of innate immune responsive genes (including IFN-gamma, T-bet, IL-12R beta 2, and IL-18R) in NK cells, priming NK cells to kill tumor cells.
[0060] To efficiently utilize IL-21, expression of mbIL-21 (Figure 4A) may be used to focus and localize trans-interactions with IL21R on NK cells. Because of its close proximity to the membrane, mbIL21 is readily available when needed, allowing optimal cell proliferation without the need for exogenous supply of large amounts and high concentrations of IL-21. Co-culture with irradiated K562-mb15-41BBL induced a median 21.6-fold expansion of CD56+CD3-NK cells from peripheral blood. This expansion is greater than stimulation with merely soluble cytokines from the shared γc family, including IL-2, IL-12, IL-15, and IL-21, alone or in combination. In comparison, the present UAPCs can expand NK cells by at least 1000-fold (3-log) over a period of 14-21 days. Expression of mbIL21 on UAPCs may also obviate the need for exogenous clinical-grade cytokines. B.4-1BBL (4-1BB ligand, CD137 ligand, CD137L, TNFSF9)
[0061] In addition to the idea of priming NK cell function with cytokines, direct physical interaction with activating molecules on NK cells also enhances cell proliferation responses. CD137 (4-1BB) is a member of the tumor necrosis receptor (TNF-R) gene family and mediates cell proliferation, differentiation and programmed cell death (apoptosis). After the mouse receptor was first characterized, the human homolog was characterized, which shares 60% identity at the amino acid level and has significant conservation of the cytoplasmic / signaling domain. CD137 is expressed primarily in activated T cells and activated NK cells, with variable levels also detectable in thymocytes, myeloid cells and endothelial cells at sites of inflammation. Physiological CD137 signaling is mediated by 1) NF-κB, which promotes survival by activating Bcl-XL, and 2) the PI3K / ERK1 / 2 pathway, which specifically drives cell cycle progression.
[0062] In activated NK cells, CD137 is a cytokine-induced costimulatory molecule that drives antitumor responses in NK cells by increasing cell proliferation and IFN-γ secretion. Studies using CD137L- / - knockout mice have elucidated the importance of CD137 / CD137L signaling in the development of antitumor immune cells. CD137- / - knockout mice showed a four-fold increased frequency of tumor metastasis compared with control mice.
[0063] CD137 ligand (CD137L, 4-1BB ligand), a 34 kDa glycoprotein member of the TNF superfamily, is primarily detected on activated antigen-presenting cells (APCs), including B cells, macrophages, and dendritic cells, and is also transiently expressed at low levels on activated T cells. Human CD137L is only 36% homologous to its murine counterpart. Consistent with the antitumor efficacy of agonistic CD137 antibodies, binding of CD137L has been shown to induce CTL and antitumor activity.
[0064] Thus, the UAPCs can be engineered to express the 4-1BB ligand, the physiological counter-receptor for CD137, for stimulation. C.SLAM / CD48
[0065] Besides cytokine conditioning and costimulation by 4-1BBL, direct physical interaction of NK cells with target cells also influences the cellular response, i.e., killing of the target cells. Homologous immunoglobulin receptors of the signaling lymphocyte activation molecule (SLAM, formerly also known as the CD2 superfamily) family, which are widely expressed and play a crucial role in the immune system, are of particular importance for cell-cell interactions.
[0066] Thus, the UAPCs of the present disclosure may express one or more SLAM family antigens. Members of the SLAM family include CD2, CD48, CD58 (LFA-3), CD244 (2B4), CD229 (Ly9), CD319 (CS1 (CD2 subset 1); CRACC (CD2-like receptor-activated cytotoxic cell)) and CD352 (NTB-A (NK-TB antigen)). In certain embodiments, the UAPCs express CD48 and / or CS1. NK cells express at least three members of the SLAM family (SLAMF). They are 2B4, NK cell, T cell and B cell antigen (NTB-A), and CD2-like receptor-activated cytotoxic cell (CRACC), which recognize their respective ligands CD48, NTB-A and CRACC on target cells and possibly on other NK cells. SLAMF1, 3, 5, 6, 7, 8, and 9 are homophilic (autoligand) receptors, whereas SLAMF2 and SLAMF4 are counterreceptors (heterophilic) for each other. The wide range (three orders of magnitude) of known homophilic affinities (dissociation constants Kd from <1 μM to 200 μM) suggests a mechanistic basis for overlapping yet distinct signaling mechanisms for SLAM glycoproteins.
[0067] Table 1: Binding affinities of SLAM family members. [Table 1]
[0068] In certain embodiments, the UAPC is engineered to express CD48 to support cell-cell interactions and enhance NK cell responses. CD48 is a glycosylphosphatidylinositol-anchored protein (GPI-AP) found on the surface of NK cells, T cells, monocytes and basophils, and is involved in adhesion and activation pathways in these cells. Despite lacking an intracellular domain, stimulation of CD48 induces rearrangement of signaling factors in lipid rafts, Lck-kinase activity and tyrosine phosphorylation. As an adhesion costimulatory molecule, CD48 induces numerous effects in B and T lymphocytes, NK cells, mast cells and eosinophils. In human NK cells, CD48 is a counter-receptor for 2B426, a key activator of NK cells. Heterophilic interactions are believed to compete for the interaction of MHC-I with CD244. Thus, 2B4 / CD48 interaction induces an activating signal in human NK cells, whereas it sends an inhibitory signal in mouse NK cells.
[0069] 2B4-CD48 interactions between cells of the same population, i.e., NK cell-NK cell or T cell-T cell interactions, enhance activation by expressing CD48 on APCs (e.g., K562 myeloid cell lineage, which normally lack CD48), but the present UAPCs can turn on the potent 2B4 signaling pathway in trans to NK cells. D.SLAM / CS1
[0070] In some embodiments, the UAPC is engineered to express CS1, another member of the SLAM family, as a costimulatory molecule that switches on the killing power of NK cells.Unlike CD48, which interacts with 2B4, CS1 interaction is homophilic and can be characterized in the context of cis versus trans interactions.K562 cells, which do not normally contain CS1, are engineered to express CS1. E. Delivery of Nucleic Acid
[0071] mbIL-21, 41BBL and costimulatory antigen can be manipulated by any method known in the art.Nucleic acid is usually administered in the form of an expression vector, such as a viral expression vector.In some embodiments, the expression vector is a retroviral expression vector, an adenoviral expression vector, a DNA plasmid expression vector or an AAV expression vector.In some embodiments, the delivery is by delivery of one or more vectors, one or more transcripts thereof and / or one or more proteins transcribed therefrom, and delivered to the cell.
[0072] Methods for introducing polynucleotide constructs into animal cells are known, including, but not limited to, stable transformation methods in which polynucleotide constructs are integrated into the genome of cells, transient transformation methods in which polynucleotide constructs are not integrated into the genome of cells, and virus-mediated methods.In some embodiments, polynucleotides can be introduced into cells, for example, by recombinant viral vectors (e.g., retroviruses, adenoviruses), liposomes, etc.For example, in some aspects, transient transformation methods include microinjection, electroporation, or particle guns.In some embodiments, polynucleotides can be included in vectors, more specifically, plasmids or viruses, in order to be expressed in cells.
[0073] Methods for non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection has been described (e.g., in U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355), and lipofection reagents are commercially available (e.g., Transfectam). TM and LipofectinTM ). Cationic and neutral lipids suitable for efficient receptor recognition lipofection of polynucleotides include Feigner's lipids, WO91117424; WO91116024. Delivery can be to cells (e.g., in vitro or ex vivo administration) or to target tissues (e.g., in vivo administration).
[0074] In some embodiments, delivery is by using RNA virus or DNA virus-based system to deliver nucleic acid.In some aspects, viral vector can be directly administered to patient (in vivo), or can be used to treat cells in vitro or ex vivo, and then administered to patient.In some embodiments, viral-based system includes retroviral vector, lentiviral vector, adenoviral vector, adeno-associated virus vector and herpes simplex virus vector for gene transfer. III. Immune cells
[0075] Some embodiments of the present disclosure relate to the isolation and expansion of immune cells (e.g., NK cells or T cells), such as for cancer immunotherapy.
[0076] In certain embodiments, immune cells are obtained from human peripheral blood mononuclear cells (PBMCs), unstimulated leukapheresis fluids (PBSCs), human embryonic stem cells (hESCs), induced pluripotent stem cells (iPSCs), bone marrow or umbilical cord blood by methods well known in the art. In particular, immune cells can be isolated from umbilical cord blood (CB), peripheral blood (PB), bone marrow or stem cells. In certain embodiments, immune cells are isolated from pooled CBs. CBs can be pooled from 2, 3, 4, 5, 6, 7, 8, 10 or more units. Immune cells can be autologous or allogeneic. Isolated immune cells can be haplotype-matched to the subject receiving cell therapy. NK cells can be detected by specific surface markers (e.g., CD16, CD56 and CD8 in humans).
[0077] In certain embodiments, NK cells are isolated by a previously reported method of ex vivo expansion of NK cells (Spanholtz et al., 2011; Shah et al., 2013). In this method, CB mononuclear cells are isolated by Ficoll density gradient centrifugation. The cell culture may be depleted of any cells expressing CD3 and expresses CD56. + / CD3 - Alternatively, umbilical CB can be used to measure the percentage of CD34 cells or NK cells. + NK cells are obtained by cell isolation, which may include depletion of CD3, CD14 and / or CD19 positive cells.
[0078] The isolated immune cells may be expanded in the presence of the UAPCs. The expansion may be for about 2 to 30 days (e.g., 3 to 20 days, particularly 12 to 16 days, e.g., 12, 13, 14, 15, 16, 17, 18 or 19 days, particularly about 14 days). The immune cells and UAPCs may be present in a ratio of about 3:1 to 1:3 (e.g., 2:1, 1:1, 1:2, particularly about 1:2). The expansion culture may further comprise a cytokine (e.g., IL-2) that promotes expansion. IL-2 may be present in a concentration of about 10 to 500 U / mL (e.g., 100 to 300 U / mL, particularly about 200 U / mL). IL-2 may be replenished to the expansion culture, for example, every 2 to 3 days. UAPCs may be added to the culture at least twice (e.g., about 7 days after expansion).
[0079] After expansion, the immune cells may be infused immediately or may be preserved, such as by cryopreservation. In certain embodiments, the cells may be expanded ex vivo as a bulk population within about 1, 2, 3, 4, 5 days, for days, weeks or months.
[0080] Expanded NK cells may secrete type I cytokines (e.g., interferon-γ, tumor necrosis factor-α, and granulocyte-macrophage colony-stimulating factor (GM-CSF)), which activate both innate and adaptive immune cells, as well as other cytokines and chemokines. Measurement of these cytokines can be used to measure the activation state of NK cells. Additionally, other methods known in the art for measuring NK cell activation may be used to characterize the NK cells of the present disclosure. IV. Chimeric Antigen Receptors
[0081] In certain embodiments, the immune cells (e.g., T cells or NK cells) are genetically modified to express a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises a) an intracellular signaling domain, b) a transmembrane domain, and c) an extracellular domain that comprises an antigen-binding region.
[0082] CARs recognize cell surface tumor-associated antigens independent of human leukocyte antigens (HLA) and activate genetically modified NK cells for killing, proliferation, and cytokine production using one or more signaling molecules. In certain embodiments, the NK cells are engineered using (i) non-viral gene transfer using an electroporation device (e.g., nucleofector), (ii) CARs that signal through an endodomain (e.g., CD28 / CD3-ζ, CD137 / CD3-ζ, or other combinations), (iii) CARs with various lengths of extracellular domains linking the antigen recognition domain to the cell surface, and, in some cases, (iv) CARs. + NK cells can be genetically modified by methods including artificial antigen presenting cells (aAPCs) derived from K562 (Singh et al., 2011) that can reliably and numerically expand NK cells.
[0083] The embodiments of the present disclosure relate to the use of nucleic acids, including nucleic acids encoding antigen-specific CAR polypeptides, including humanized CARs (hCARs) that include an intracellular signaling domain, a transmembrane domain, and an extracellular domain that includes one or more signaling motifs to reduce immunogenicity. In certain embodiments, the CAR may recognize an epitope that includes a space shared between one or more antigens. In certain embodiments, the binding region may include a complementarity determining region of a monoclonal antibody, a variable region of a monoclonal antibody, and / or an antigen-binding fragment thereof. In another embodiment, the specificity is derived from a peptide (e.g., a cytokine) that binds to a receptor.
[0084] It is contemplated that the human CAR nucleic acid may be a human gene used to improve cellular immunotherapy for human patients. In a specific embodiment, the method uses a full-length CAR cDNA or coding region. The antigen-binding region or domain is the V of a single-chain variable fragment (scFv) derived from a particular human monoclonal antibody (e.g., as described in U.S. Patent No. 7,109,304, which is incorporated herein by reference). H Chain and V L The fragments may include fragments of the chains of a human antigen-specific antibody. The fragments may also be any number of different antigen-binding domains of a human antigen-specific antibody. In a more specific embodiment, the fragments are antigen-specific scFvs encoded by sequences optimized for human codon usage for expression in human cells.
[0085] The configuration can be a multimer, for example, a diabody or multimer. Multimers are usually formed by pairing the variable parts of light and heavy chains with each other to become a diabody. The hinge part of the construct has several options, including being completely deleted, maintaining the first cysteine, substituting proline instead of serine, and being truncated to the first cysteine. The Fc part can be deleted. Any protein that is stable and / or dimerizes can serve this purpose. One of the Fc domains can be used, for example, either the CH2 or CH3 domain from a human immunoglobulin. The hinge, CH2 and CH3 regions of a human immunoglobulin that have been modified to improve dimerization can be used. In other embodiments, simply the hinge part of an immunoglobulin or a portion of CD8α can be used.
[0086] In some embodiments, the CAR nucleic acid comprises a sequence encoding other costimulatory receptors (e.g., transmembrane domains and modified CD28 intracellular signaling domains). Other costimulatory receptors include, but are not limited to, one or more of CD28, CD27, OX-40 (CD134), DAP10 and 4-1BB (CD137). In addition to the primary signal elicited by CD3ζ, the additional signal provided by the human costimulatory receptor inserted into the human CAR is important for the full activation of NK cells and can help improve in vivo persistence and the success of adoptive immunotherapy treatment.
[0087] The intracellular signaling domain of the chimeric antigen receptor is involved in the activation of at least one of the normal effector functions of the immune cell to which the chimeric antigen receptor is placed. The effector function is a specialized function of differentiated cells such as NK cells. In a specific embodiment, the intracellular receptor signaling domain in the CAR includes the intracellular receptor signaling domain of the T cell antigen receptor complex (e.g., the zeta chain of CD3, and also the FcγRIII costimulatory signaling domain, CD28, CD27, DAP10, CD137, OX40, CD2, alone or in series with, for example, CD3 zeta). In a specific embodiment, the intracellular domain (which may be referred to as the cytoplasmic domain) comprises part or all of one or more of TCR zeta chain, CD28, CD27, OX40 / CD134, 4-1BB / CD137, FcεRIγ, ICOS / CD278, IL-2R beta / CD122, IL-2R alpha / CD132, DAP10, DAP12, and CD40. Any part of the endogenous T cell receptor complex may be used in the intracellular domain. The so-called third generation CARs have at least two or three signaling domains fused together, for example, for additive or synergistic effects, and therefore may use one or more cytoplasmic domains.
[0088] In certain embodiments of the CAR, the antigen-specific portion of the receptor (which may be referred to as the extracellular domain containing the antigen-binding region) comprises a tumor-associated antigen or a pathogen-specific antigen-binding domain. Antigens include carbohydrate antigens recognized by pattern recognition receptors such as Dectin-1. The tumor-associated antigen may be of any type, as long as it is expressed on the cell surface of tumor cells. The tumor antigen binding domain can be, but is not limited to, CD19, CD20, carcinoembryonic antigen, alpha fetoprotein, CA-125, MUC-1, epithelial tumor antigen, melanoma associated antigen, mutated p53, mutated ras, HER2 / Neu, ERBB2, folate binding protein, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, GD2, CD123, CD23, CD30, CD56, c-Met, mesothelin, GD3, HERV-K, IL-11R alpha, kappa chain, lambda chain, CSPG4, ERBB2, EGFRvIII, or VEGFR2. The CAR can include a humanized scFv (e.g., humanized CD19 or CD123).
[0089] In certain embodiments, the CAR can be co-expressed with cytokines to improve survival when the amount of tumor-associated antigen is low. For example, the CAR can be co-expressed with IL-15.
[0090] The sequence of the open reading frame encoding the chimeric receptor can be obtained from genomic DNA sources, cDNA sources, or can be synthesized (e.g., via PCR), or a combination thereof. Depending on the size of the genomic DNA and the number of introns, it may be desirable to use cDNA or a combination thereof, since introns have been found to stabilize mRNA. It may also be further beneficial to use endogenous or foreign non-coding regions to stabilize mRNA.
[0091] It is contemplated that chimeric constructs can be introduced into NK cells as naked DNA or in the form of suitable vectors.Methods for stably transfecting cells by electroporation using naked DNA are known in the art.See, for example, U.S. Patent No. 6,410,319.Naked DNA generally refers to the DNA that codes for chimeric receptors, which is included in a plasmid expression vector in the proper orientation for expression.
[0092] Alternatively, the chimeric construct can be introduced into NK cells by using a viral vector (e.g., retroviral vector, adenoviral vector, adeno-associated viral vector or lentiviral vector). The vector suitable for use according to the method of the present invention is non-replicative in NK cells. Many vectors based on viruses are known, and the copy number of the virus maintained in the cell is low enough to maintain the viability of the cell, such as HIV, SV40, EBV, HSV or BPV-based vectors.
[0093] The CAR may express a suicide gene (e.g., CD20, CD52, EGFRv3 or inducible caspase 9).
[0094] The CAR may comprise a tumor antigen binding domain, which may be, but is not limited to, CD19, CD20, carcinoembryonic antigen, alpha fetoprotein, CA-125, MUC-1, epithelial tumor antigen, melanoma associated antigen, mutated p53, mutated ras, HER2 / Neu, ERBB2, folate binding protein, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, GD2, CD123, CD23, CD30, CD56, c-Met, mesothelin, GD3, HERV-K, IL-11R alpha, kappa chain, lambda chain, CSPG4, ERBB2, EGFRvIII, or VEGFR2. The CAR can comprise a humanized scFv, such as humanized CD19, CD123, mesothelin, CD5, CD47, CLL-1, CD33, CD99, U5snRNP200, CD200, CS1, BAFF-R, ROR-1 or BCMA. V. How to use
[0095] An embodiment of the present disclosure relates to a method for using immune cells, such as NK or T cells (e.g., expanded by the present UAPC), provided herein to treat or prevent a medical disease or disorder by transferring an immune cell population that induces an immune response. The method includes administering to a subject a therapeutically effective amount of the expanded immune cells, thereby treating or preventing the disorder in the subject. In a certain embodiment of the present disclosure, cancer or infectious disease is treated by transferring an immune cell population that induces an immune response. The immune cells can reverse the anti-inflammatory tumor microenvironment by promoting the differentiation, activation and / or recruitment of auxiliary immune cells to the site of malignancy due to the release of pro-inflammatory cytokines, and can enhance adaptive immune responses.
[0096] The tumors that this treatment method is useful for include any malignant cell type, such as those found in solid tumors or blood tumors.Exemplary solid tumors may include, but are not limited to, tumors of organs selected from the group consisting of pancreas, colon, appendix, stomach, brain, head, neck, ovary, kidney, larynx, sarcoma, lung, bladder, melanoma, prostate and breast.Exemplary blood tumors include bone marrow tumors, T or B cell malignancies, leukemia, lymphoma, blastoma, myeloma, etc. Further examples of cancers that can be treated using the methods provided herein include, but are not limited to, lung cancer (including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma), cancer of the peritoneum, gastric or stomach cancer (including digestive and gastrointestinal stromal cancer), pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, renal or kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, various types of head and neck cancer, and melanoma.
[0097] The cancer may specifically be of the following histological types, but is not limited to: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant cell and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; mixed hepatocellular carcinoma-cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenomatous intrapolypoid adenocarcinoma; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; bronchioloalveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophilic carcinoma; acidophilic adenocarcinoma; basophilic carcinoma; clear cell adenocarcinoma; granular cellular carcinoma. follicular carcinoma;follicular adenocarcinoma;papillary-follicular adenocarcinoma;nonencapsulated sclerosing carcinoma;adrenal cortical carcinoma;endometrioid carcinoma;adnexal carcinoma;apocrine gland carcinoma;sebaceous gland carcinoma;earwax gland carcinoma;mucoepidermoid carcinoma;cystadenocarcinoma;papillary cystadenocarcinoma;papillary serous cystadenocarcinoma;mucinous cystadenocarcinoma;mucinous adenocarcinoma;signet ring cell carcinoma;invasive ductal carcinoma;medullary carcinoma;lobular carcinoma;inflammatory carcinoma;Paget's disease, breast;acinic cell carcinoma;adenosquamous carcinoma;adenocarcinoma with squamous metaplasia;thymoma, malignant;ovarian stromal tumor, malignant;theca cell tumor, malignant;granulosa cell tumor, malignant;androblastoma, malignant;Sertoli cell carcinoma;Leydig cell tumor, malignant;lipid cell tumor, malignant;paracellular Ganglionoma, malignant;Extramammary paraganglioma, malignant;Pheochromocytoma;Glomus angiosarcoma;Malignant melanoma;Amelanotic melanoma;Superficial spreading melanoma;Lentigo maligna melanoma;Acral lentigo melanoma;Nodular melanoma;Malignant melanoma in giant pigmented nevus;Epithelioid cell melanoma;Blue nevus, malignant;Sarcoma;Fibrosarcoma;Fibrous histiocytoma, malignant;Myxosarcoma;Liposarcoma;Leiomyosarcoma;Rhabdomyosarcoma;Embryonal rhabdomyosarcoma;Alveolar rhabdomyosarcoma;Stroma sarcoma;Mixed tumor, malignant;Mullerian mixed tumor;Nephroblastoma;Hepatoblastoma;Carcinosarcoma;Mesenchymoma, malignant;Brenner tumor, malignant;Phyllodes tumor, malignant;Synovial sarcoma;Mesothelioma, malignant;Dysplastic germ cell Cystoma;Embryonal carcinoma;Teratoma, malignant;Ovarian goiter, malignant;Choriocarcinoma;Mesonephroma, malignant;Angiosarcoma;Hemangioendothelioma, malignant;Kaposi's sarcoma;Hemangiopericytoma, malignant;Lymphangiosarcoma;Osteosarcoma;Paracortical osteosarcoma;Chondrosarcoma;Chondrosarcoma, malignant;Mesenchymal chondrosarcoma;Giant cell tumor of bone;Ewing's sarcoma;Odontogenic tumor, malignant;Ameloblastoma, malignant;Ameloblastoma, malignant;Ameloblastoma;Pinealoma, malignant;Chordoma;Glioma, malignant;Ependymoma;Astrocytoma;Protoplasmic astrocytoma;Fibrillary astrocytoma;Astroblastoma;Glioblastoma;Oligodendroglioma;Oligodendroglioma;Primitive neuroectodermal;Cerebellar sarcoma;Ganglioneuroblastoma;Neuroblastoma;Retinoblastoma;Olfactory neurogenic tumor;Meningioma, malignant;Neurofibrosarcoma;Neurilemoma, malignant;Granular cell tumor, malignant;Malignant lymphoma;Hodgkin's disease;Hodgkin's lymphoma;Side granuloma;Malignant lymphoma, small lymphocytic;Malignant lymphoma, large cell, diffuse;Malignant lymphoma, follicular;Mycosis fungoides;Other specified non-Hodgkin's lymphoma;B-cell lymphoma;Low-grade / follicular non-Hodgkin's lymphoma (NHL);Small lymphocytic (SL) NHL;Intermediate-grade / follicular NHL;Intermediate-grade diffuse NHL;High-grade immunoblastic NHL;High-grade lymphoblastic NHL;High-grade small noncleaved cell NHL;Bulky disease disease)NHL;mantle cell lymphoma;AIDS-related lymphoma;Waldenstrom's macroglobulinemia;malignant histiocytosis;multiple myeloma;mast cell sarcoma;immunoproliferative small intestinal disease;leukemia;lymphocytic leukemia;plasma cell leukemia;erythroleukemia;lymphoblastic cell leukemia;myeloid leukemia;basophilic leukemia;eosinophilic leukemia;monocytic leukemia;mast cell leukemia;megakaryoblastic leukemia;myeloid sarcoma;hairy cell leukemia;chronic lymphocytic leukemia (CLL);acute lymphoblastic leukemia (ALL);acute myeloid leukemia (AML);and chronic myeloblastic leukemia. ;
[0098] Certain embodiments relate to methods of treating leukemia. Leukemia is a cancer of the blood or bone marrow, characterized by abnormal proliferation (production by division) of blood cells, usually white blood cells (leukocytes). Leukemia is part of a broad group of diseases called hematological neoplasms. Leukemia is a broad term that covers a range of diseases. Clinically and pathologically, leukemia is divided into acute and chronic forms.
[0099] Acute leukemia is characterized by the rapid proliferation of immature blood cells. This crowding prevents the bone marrow from producing healthy blood cells. Acute forms of leukemia can occur in children and young adults. Rapid progression and accumulation of malignant cells that then spill into the bloodstream and spread to other organs of the body require immediate treatment. Central nervous system (CNS) involvement is uncommon, but the disease can occasionally cause cranial nerve palsies. Chronic leukemia is distinguished by an excessive accumulation of relatively mature but still abnormal blood cells. During its progression, which usually takes months to years, cells are produced at a much faster rate than normal cells, resulting in many abnormal white blood cells in the blood. Chronic leukemia most often occurs in older people, but theoretically can occur in any age group. Acute leukemia must be treated immediately, whereas chronic forms are sometimes monitored for some time before treatment to ensure that the effectiveness of the treatment is maximized.
[0100] The diseases are further classified as lymphocytic or lymphoblastic (referring to the transformation of a type of bone marrow cell that normally continues to give rise to lymphocytes) and myeloid or myeloid (referring to the transformation of a type of bone marrow cell that normally continues to give rise to red blood cells, some types of white blood cells, and platelets).
[0101] Acute lymphocytic leukemia (also known as acute lymphoblastic leukemia, or ALL) is the most common type of leukemia in young children. The disease also occurs in adults, especially those over 65 years of age. Chronic lymphocytic leukemia (CLL) occurs most often in adults over 55 years of age. Chronic lymphocytic leukemia (CLL) occasionally occurs in younger adults, but rarely in children. Acute myelogenous leukemia (also known as acute myeloid leukemia, or AML) usually occurs in adults rather than children. This type of leukemia was previously called acute nonlymphocytic leukemia. Chronic myelogenous leukemia (CML) occurs primarily in adults.
[0102] Lymphoma is a type of cancer that develops from lymphocytes, a type of white blood cell in the immune system of vertebrates. There are many types of lymphoma. According to the National Institutes of Health, lymphoma accounts for about 5 percent of all cancer cases in the United States, with Hodgkin's lymphoma accounting for less than 1 percent of all cancer cases in the United States. Because the lymphatic system is part of the body's immune system, patients with weakened immune systems, such as those with HIV infection or certain drugs or drug therapies, also have a high incidence of lymphoma.
[0103] In certain embodiments of the present disclosure, immune cells are delivered to an individual in need thereof (e.g., an individual with cancer or infectious disease). These cells then stimulate the individual's immune system to attack the respective cancer cells or pathogenic cells. In some cases, an individual is provided with immune cells one or more times. If an individual is provided with immune cells two or more times, the time between administrations should be sufficient to allow time for propagation in the individual, and in specific embodiments, the time between administrations is 1, 2, 3, 4, 5, 6, 7 days or more.
[0104] The source of the preactivated and expanded immune cells can be of any type, but in specific embodiments, the cells are obtained, for example, from umbilical cord blood, peripheral blood, a bank of human embryonic stem cells or induced pluripotent stem cells. A suitable dose for therapeutic effect is preferably at least 10 mg / dose, preferably in a series of administration cycles. 5 or about 10 5 ~about 10 10 An exemplary dosing regimen includes at least about 10 days on day 0. 5 Starting with cells, for example, within a few weeks of initiating an intrapatient dose escalation scheme, approximately 10 10 The treatment consists of four weekly cycles of escalating doses, gradually increasing the target dose of cells. Suitable modes of administration include intravenous, subcutaneous, intracavitary (e.g., reservoir access device), intraperitoneal, and direct injection into the tumor mass.
[0105] In one exemplary method, NK cells can be derived from a biological sample, such as one or more cord blood units. The cord blood unit can be a frozen cord blood unit. The cord blood unit can be thawed and subjected to a Ficoll gradient to obtain mononuclear cells. The mononuclear cells can be depleted of CD3, CD14 and CD19 positive cells, such as by CliniMAS. The negatively selected NK cells can then be cultured in the presence of APC and IL-2 (e.g., 200 U / mL). The NK cells can then be transduced with a retroviral supernatant expressing a CAR and cultured with gamma-irradiated APC and IL-2. Finally, the cells can be sorted for positive expression of a CAR (e.g., CD56, CD16, CD3, CD19, CD14 or CD45).
[0106] The immune cells produced according to the present method have many potential uses, including experimental and therapeutic uses. In particular, it is envisioned that such cell populations will be extremely useful in suppressing undesirable or inappropriate immune responses. In such methods, a small number of immune cells are removed from a patient, then manipulated and expanded ex vivo, and then reinjected into the patient. Examples of diseases that can be treated in this way are autoimmune diseases and conditions in which suppression of immune activity is desired, for example, for allograft tolerance. Therapeutic methods can include the steps of providing a mammal, obtaining immune cells from the mammal; expanding the immune cells ex vivo according to the method of the present method described above; and administering the expanded immune cells to the mammal to be treated.
[0107] The pharmaceutical compositions of the present disclosure may be used alone or in combination with other established agents useful in the treatment of cancer. Whether delivered alone or in combination with other agents, the pharmaceutical compositions of the present disclosure may be delivered to various sites of the mammalian, particularly human, body via various routes to achieve a particular effect. Those skilled in the art will recognize that, although more than one route may be used for administration, certain routes may provide a more immediate and effective response than another route. For example, in the case of the treatment of melanoma, intradermal delivery may be advantageously used rather than inhalation. Local or systemic delivery may be achieved by administration, including application or instillation of the formulation into body cavities, inhalation or insufflation of aerosols, or parenteral introduction, including intramuscular, intravenous, intraportal, intrahepatic, peritoneal, subcutaneous or intradermal administration.
[0108] Certain embodiments of the present disclosure provide methods for treating or preventing an immune-mediated disorder. In one embodiment, the subject has an autoimmune disease. Non-limiting examples of autoimmune diseases include alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune disease of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac disease, chronic fatigue immune deficiency syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA neuropathy, juvenile arthritis, lichen planus, lupus erythema todes, Meniere's disease, mixed connective tissue disease, multiple sclerosis, type 1 or immune-mediated diabetes mellitus, myasthenia gravis, nephrotic syndrome (e.g. minimal change disease, focal glomerulosclerosis or membranous nephropathy), pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, Include psoriasis, psoriatic arthritis, Raynaud's phenomenon, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff-body syndrome, systemic lupus erythematosus, lupus erythematosus, ulcerative colitis, uveitis, vasculitis (e.g. polyarteritis nodosa, Takayasu's arteritis, temporal arteritis / giant cell arteritis or dermatitis herpetiformis vasculitis), vitiligo, and Wegener's granulomatosis.Thus, some examples of autoimmune diseases that can be treated using the methods disclosed herein include, but are not limited to, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, Crohn's disease; ulcerative colitis, myasthenia gravis, glomerulonephritis, ankylosing spondylitis, vasculitis or psoriasis.Subjects may also have allergic disorders, such as asthma.
[0109] In yet another embodiment, the subject is a recipient of an organ transplant or stem cell transplant, and the immune cells are used to prevent and / or treat rejection. In certain embodiments, the subject has or is at risk of developing graft-versus-host disease. GVHD is a complication that can occur in any transplant that uses or includes stem cells from related or unrelated donors. There are two types of GVHD: acute and chronic. Acute GVHD appears within the first three months after transplant. Signs of acute GVHD include a reddish rash on the hands and feet, which can spread and become more severe, with skin peeling or blistering. Acute GVHD can also affect the stomach and intestines, where muscle cramps, nausea, and diarrhea appear. Yellowing of the skin and eyes (jaundice) indicates that acute GVHD is affecting the liver. Chronic GVHD is graded based on its severity: stage / grade 1 is mild; stage / grade 4 is severe. Chronic GVHD develops 3 months or later after transplantation. Symptoms of chronic GVHD are similar to those of acute GVHD, but chronic GVHD can also affect the mucous glands of the eye, the salivary glands of the mouth, and the glands that lubricate the stomach lining and intestines. Any population of immune cells disclosed herein can be utilized. Examples of transplanted organs include solid organ transplants (e.g., kidney, liver, skin, pancreas, lung, and / or heart) or cell transplants (e.g., pancreatic islets, hepatocytes, myoblasts, bone marrow, or hematopoietic or other stem cells). Transplants can be composite transplants (e.g., facial tissue). Immune cells can be administered before, at the same time, or after transplantation. In some embodiments, the immune cells are administered prior to transplantation (e.g., at least 1 hour, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, or at least 1 month prior to transplantation). In one specific, non-limiting example, administration of a therapeutically effective amount of immune cells occurs 3-5 days prior to transplantation.
[0110] In certain embodiments, immune cells are administered in combination with a second therapeutic agent.For example, the second therapeutic agent can include T cells, immunomodulatory agents, monoclonal antibodies or chemotherapeutic agents.In a non-limiting example, the immunomodulatory agent is lenolidomide, the monoclonal antibody is rituximab, ofatumab or lumiliximab, and the chemotherapeutic agent is fludarabine or cyclophosphamide.
[0111] The composition of the present disclosure can be provided in unit dosage form, where each dosage unit, for example, injection, contains a predetermined amount of the composition alone or in appropriate combination with other active agents.The term unit dosage form as used herein refers to a physically discrete unit suitable as a unitary dosage for human and animal subjects, each unit containing a predetermined amount of the composition of the present invention, calculated as an amount sufficient to produce a desired effect, alone or in combination with other active agents, optionally together with a pharma- ceutically acceptable diluent, carrier or vehicle.The specification for the novel unit dosage form of the present invention depends on the specific pharmacodynamics associated with the pharmaceutical composition in a specific subject.
[0112] Desirably, an effective amount or sufficient number of the isolated and introduced immune cells are present in the composition and introduced into the subject such that a long-term specific anti-tumor response is established and tumor size is reduced or tumor growth or regrowth that may occur in the absence of such treatment is eliminated. Desirably, the amount of immune cells reintroduced into the subject reduces tumor size by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 100% compared to otherwise the same conditions (no immune cells present).
[0113] Thus, the amount of immune cells administered should take into account the route of administration and should be such that a sufficient number of immune cells are introduced to achieve the desired therapeutic response. Furthermore, the amount of each active agent included in the compositions described herein (e.g., the amount per each cell contacted or the amount per a certain body weight) may vary depending on the application. In general, the concentration of immune cells is desirably at least about 1×10 in the subject to be treated. 6 ~Approx. 1×10 9 Immune cells, even more preferably about 1×10 7 ~Approx. 5×10 8 The amount should be sufficient to provide immune cells, but more than 5×10 8 More than or less than 1 x 10 cells 7 Any suitable amount can be utilized, including subcellular amounts. Administration schedules can be based on established cell-based therapies (see, e.g., Topalian and Rosenberg, 1987; U.S. Patent No. 4,690,915), or alternative continuous infusion strategies can be used.
[0114] These values provide general guidance for the range of immune cells that practitioners utilize when optimizing the method of the present invention to carry out the present invention. The specification of such ranges in no way precludes the use of greater or lesser amounts of components that may be warranted in a particular application. For example, the exact dose and schedule may vary depending on whether the composition is administered in combination with other pharmaceutical compositions, or depending on individual differences in pharmacokinetics, drug disposition and metabolism. Those skilled in the art can easily make any necessary adjustments depending on the exigencies of a particular situation. VI. Kit
[0115] In some embodiments, kits are provided that may include one or more media and components for making UAPCs and / or immune cells, for example. Such formulations may include a cocktail of factors in a form suitable for combining with APCs and / or immune cells. The reagent system may be packaged in aqueous media or in lyophilized form, as appropriate. The container means of the kit generally includes at least one vial, test tube, flask, bottle, syringe or other container means into which the components may be placed, preferably appropriately dispensed. When there is more than one component in the kit, the kit generally also includes a second, third or other additional container into which additional components may be placed separately. However, various combinations of components may be included in one vial. The components of the kit may be provided as dry powders. When the reagents and / or components are provided as dry powders, the powder may be reconstituted by adding a suitable solvent. It is envisioned that the solvent may be provided in another container means. The kit may also include a means for containing the components of the kit in close confinement, typically for commercial sale. Such containers can include injection or blow molded plastic containers into which the desired vials are retained. The kit can also include instructions for use (e.g., in printed or electronic form, e.g., digital form). EXAMPLES
[0116] VII. Examples The following examples are included to demonstrate preferred embodiments of the invention. It should be recognized by those skilled in the art that the procedures disclosed in the following examples are procedures that the inventors have discovered to work well in the practice of the invention, and therefore may be considered to constitute preferred modes for carrying out the invention. However, those skilled in the art should recognize, in light of this disclosure, that many changes may be made in the specific embodiments disclosed without departing from the spirit and scope of the invention and still obtain the same or similar results.
[0117] Example 1 - Combination of mbIL21, 4-1BBL and SLAM (CD48 / CS1) Universal antigen-presenting cells (UAPCs) were generated by transducing K562 cells with retroviral constructs against membrane-bound IL-21 and 41BBL (CD137 ligand) together with either CD48-Katushka or CS1-EGFP. Maps and annotations of MMLV-retroviral constructs are shown in Figures 4A-4D. NK cell-sensitive K562 (HLA-A - , HLA-B - Forced expression of mbIL-21 and 41BBL in .APC (Figure 3A) generated clone 46 (Figure 3B). Forced expression of mbIL-1, 41BBL, and CD48 in K562 cells generated UAPC (Figure 3C). Forced expression of mbIL-21, 41BBL, and CS1 in K562 cells generated UAPC2 (Figure 3D).
[0118] Numerical expansion of NK cells was performed using activation with clone 46, UAPC or UAPC2. NK cell proliferation and expansion by APC coculture showed that clone 46 has a superior ability to expand both non-transduced NK cells (NT-NK) and CAR-transduced NK cells (SG4-NK) compared to the previously published clone 9 (Figure 2B).
[0119] NK cell expansion by co-culture with UAPCs was shown to be superior in its ability to reduce NK cell doubling time to 31.38 h compared to the previously published clone 9 (doubling time of 33 h) and provided a 44% proliferative advantage over 2 weeks (1671-fold expansion for UAPCs vs. 1161-fold expansion for clone 9) (Figure 2E). The relationship between doubling time and expansion fold to starting cell population can be simplified by the following equation:
number
[0120] In the formula, N fis the final cell number, N b are the starting cells, e = 2.71828 (a mathematical constant also known as Euler's number), T is the time span of the culture in hours, T D is the doubling time in hours. Doubling time exponentially affects the final cell number, thus providing a greater proliferative advantage over a given cell culture period, allowing for the collection of clinically relevant numbers of cells in a compressed time frame. Thus, the method allows for the efficient generation of NK cells by co-culture with UAPCs.
[0121] This platform technology provides a practical method to generate large numbers of clinical-grade, highly functional and cytotoxic NK cells for cancer immunotherapy utilizing specific therapeutic combinatorial pathways. The expanded cells are 100% NK cells with no detectable T cells, avoiding unintended graft-versus-host side effects common to many immune cell preparations.
[0122] All of the methods disclosed and claimed herein can be implemented and performed without undue experimentation in light of this disclosure. Although the compositions and methods of the present invention have been described with reference to preferred embodiments, it will be apparent to those skilled in the art that modifications may be applied to the methods and steps or steps of the methods described herein without departing from the concept, spirit and scope of the present invention. More specifically, it will be apparent that certain chemically and physiologically related agents may be substituted for the agents described herein while still achieving the same or similar results. All such similar substitutions and modifications that are apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the present invention as defined by the appended claims.
[0123] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. Czerkinsky et al., J. Immunol. Methods 1988;110:29-36. Fast et al., Transfusion 2004;44:282-5. He Y, et al. Journal of immunology research. 2014;2014:7. International Publication No. PCT / US95 / 01570 International Publication No. WO2000 / 06588 International Publication No. WO2005 / 035570 Olsson et al. J. Clin. Invest. 1990;86:981-985. Taitano et al., The Journal of Immunology, 196, 2016. U.S. Patent No. 5,939,281 U.S. Patent No. 6,218,132 U.S. Patent No. 6,264,951 U.S. Patent No. 7,488,490 U.S. Patent Publication No. 2007 / 0078113
Claims
1. A method for expanding NK cells, comprising culturing and proliferating the NK cells through cell-cell interaction in the presence of an effective amount of K562 cells that have been stably transformed by retroviral introduction and engineered to express (1) CD48 and / or CS1 (CD319), (2) membrane-bound interleukin-21 (mbIL-21), and (3) 41BB ligand (41BBL) on the cell surface.
2. The method of claim 1, wherein the NK cells and the K562 cells are cultured at a ratio of 3:1 to 1:
3.
3. The method of claim 1, wherein the expansion is in the presence of IL-2.
4. The method of claim 3, wherein the IL-2 is present at a concentration of 10 to 500 U / mL.
5. The method of claim 1 , wherein the K562 cells are added at least twice.
6. The method of claim 1, wherein the NK cells are derived from umbilical cord blood (CB), peripheral blood (PB), or stem cells.
7. 7. The method of claim 6, wherein the CB is pooled from two or more individual cord blood units.
8. The method of claim 1 , wherein the NK cells are CB mononuclear cells (CBMCs).
9. NK cells further express CD56 + The method of claim 1 , wherein the cells are defined as NK cells.
10. The method of claim 1 , wherein the K562 cells are irradiated.
11. The method of claim 1, wherein the retroviral introduction is achieved by a retroviral vector comprising pSFG-CS1-EGFP.
Citation Information
Patent Citations
A method for generating natural killer cells from stem cells.
JP2015519890A
Methods and compositions for natural killer cells
JP2017532353A
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2018013797A1
